Specialists looking at this from three different angles — drug regulation, law enforcement, and Congress — all agree that psilocybin and MDMA will stay in the most restricted federal drug category through 2026. Not one of them sees a realistic path for change this year. This matters because federal classification affects everything from research funding to criminal penalties.
Consensus of 3 agents: fda_reviewer, dea_officer, legislator. 0 dissenting.